Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

About this update from Sumitomo Pharma Co.ltd.

[{"type":"image","alt":"Knight Therapeutics","displaySize":"","headline":null,"caption":"Knight Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nIp9.tgiE4HLNmyfEs7DtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79}},"lazy":false},{"type":"text","content":"MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE® (relugolix/estradiol/norethindrone acetate) in Canada.","length":254,"tagName":"p"},{"type":"text","content":"In June 2024, Knight and Sumitomo Pharma America Inc. (“SMPA”) announced that Knight and SMPA’s affiliates had entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products (the “Mature Products”, together with MYFEMBREE®, ORGOVYX® and vibegron, the “Products”).","length":472,"tagName":"p"},{"type":"text","content":"MYFEMBREE® is a fixed-dose combination of relugolix, estradiol, and norethindrone acetate and is the first oral prescription treatment for both the management of heavy menstrual bleeding associated with uterine fibroids and the management of moderate to severe pain associated with endometriosis in pre-menopausal women. MYFEMBREE® was approved by Health Canada in September of 2023 and was launched in February 2024. Based on IQVIA, the total gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist sales for endometriosis and uterine fibroids in Canada is estimated at $45 million and has been growing at a five-year CAGR of 8%. According to IQVIA Canada, in 2024, the sales of MYFEMBREE® were approximately $2.9 million.","length":737,"tagName":"p"},{"type":"text","content":"“The relaunch of MYFEMBREE® provides physicians an effective treatment option for the management of uterine fibroids and endometriosis, conditions that continue to impact so many women,” said Samira Sakhia, Pres...

More updates from Sumitomo Pharma Co.ltd.